AUTL Autolus Therapeutics plc ADRs

Autolus Therapeutics Plc, a clinical-stage biopharmaceutical company, is developing next-generation programmed T cell therapies. It has a pipeline of product candidates in development for the treatment of haematological malignancies and solid tumors. The company was founded in 2014 and is headquartered in London, the United Kingdom. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$2.60  -0.11 (-4.06%)
As of 05/24/2022 15:56:20 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  United Kingdom
Country of incorporation:  
IPO date:  06/22/2018
Outstanding shares:  90,907,830
Average volume:  235,942
Market cap:   $249,087,454
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      BFMLGR4

---

Valuation   (See tab for details)

---

PE ratio:   -3.29
PB ratio:   0.91
PS ratio:   106.90
Return on equity:   -53.81%
Net income %:   -6,261.46%